Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19

NCT04414124 is registered in ClinicalTrials.gov with Kaleido Biosciences as lead sponsor.

NCT NCT04414124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04414124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19
Lead sponsor
Kaleido Biosciences
Phase
Not applicable
Overall status
Completed
Start date
August 2, 2020
Completion date
February 2, 2021
Enrollment
350 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

mild-to-moderate covid-19